Isorhamnetin and anti-PD-L1 antibody dual-functional mesoporous silica nanoparticles improve tumor immune microenvironment and inhibit YY1-mediated tumor progression

BACKGROUND: The immune checkpoint inhibitor (ICI) anti-PD-L1 monoclonal antibody can inhibit the progress of hepatocellular carcinoma (HCC). Epithelial–mesenchymal transformation (EMT) can promote tumor migration and the formation of immune-suppression microenvironment, which affects the therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Huijuan, Han, Jingxia, Lv, Ying, Zhao, Zihan, Zheng, Shaoting, Sun, Yu, Sun, Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10321013/
https://www.ncbi.nlm.nih.gov/pubmed/37408047
http://dx.doi.org/10.1186/s12951-023-01967-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10321013/
https://www.ncbi.nlm.nih.gov/pubmed/37408047
http://dx.doi.org/10.1186/s12951-023-01967-3

Ejemplares similares